Getinge (OTCMKTS:GNGBY – Get Free Report) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its peers? We will compare Getinge to similar businesses based on the strength of its risk, analyst recommendations, valuation, dividends, institutional ownership, earnings and profitability.
Profitability
This table compares Getinge and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Getinge | 8.20% | 11.55% | 6.15% |
| Getinge Competitors | -7.87% | -135.89% | -1.58% |
Risk and Volatility
Getinge has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Getinge’s peers have a beta of 0.98, suggesting that their average share price is 2% less volatile than the S&P 500.
Dividends
Getinge pays an annual dividend of $0.29 per share and has a dividend yield of 1.0%. Getinge pays out 26.4% of its earnings in the form of a dividend. As a group, “Healthcare Providers & Services” companies pay a dividend yield of 1.4% and pay out 25.8% of their earnings in the form of a dividend. Getinge lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.
Institutional and Insider Ownership
56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Getinge and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Getinge | $3.57 billion | $230.87 million | 25.37 |
| Getinge Competitors | $19.23 billion | $301.67 million | -1.64 |
Getinge’s peers have higher revenue and earnings than Getinge. Getinge is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Getinge and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Getinge | 0 | 4 | 0 | 0 | 2.00 |
| Getinge Competitors | 1880 | 7755 | 13395 | 833 | 2.55 |
As a group, “Healthcare Providers & Services” companies have a potential upside of 12.76%. Given Getinge’s peers stronger consensus rating and higher probable upside, analysts plainly believe Getinge has less favorable growth aspects than its peers.
Summary
Getinge peers beat Getinge on 11 of the 15 factors compared.
Getinge Company Profile
Getinge is a Swedish medical technology company that develops products and services for hospitals and life science organizations. Its offerings support patient care, surgical procedures, infection prevention and the production of medicines and other biological products. The company’s portfolio includes equipment and solutions for intensive care, cardiovascular procedures and operating rooms, as well as sterilization and cleaning systems. Its life science business provides solutions used in areas such as pharmaceutical and biotechnology manufacturing.
Receive News & Ratings for Getinge Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Getinge and related companies with MarketBeat.com's FREE daily email newsletter.
